Cadrenal Therapeutics, Inc. Banner Image

Cadrenal Therapeutics, Inc.

  • Ticker CVKD
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cadrenal Therapeutics, Inc. Logo Image
  • 1-10 Employees
  • Based in Ponte Vedra, Florida
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) with orphan drug and Fast Track designations for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease, or ESKD, and atrial fibrillation. Tecarfarin is specifically designed to leverage a different metabolismMore pathway than the oldest and most commonly prescribed Vitamin K antagonist (warfarin) used in the prevention of thrombosis. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease (CKD).
Cadrenal Therapeutics, Inc.

Most Recent Annual Report

Cadrenal Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K
Cadrenal Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!